Skip to main content
Clinical Trials/ACTRN12622000652774
ACTRN12622000652774
Recruiting
未知

Investigating the effects of synbiotic supplementation on functional movement, strength and muscle health in older Australians

Swinburne University of Technology0 sites74 target enrollmentMay 3, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
sarcopenia
Sponsor
Swinburne University of Technology
Enrollment
74
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 3, 2022
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Evidence of a personally signed and dated informed consent form (ICF) indicating that the subject has been informed of all pertinent aspects of the study.
  • 2\.Healthy adults\* who are determined by medical history and clinical judgment of the investigator to be eligible for inclusion in the study.
  • \*Note: Healthy subjects with pre\-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease within 6 weeks before enrolment, can be included.
  • 3\.Male and female adults between ages of 60 and 85 years of age (inclusive) at the time of enrolment (signing of the ICF).
  • 4\.Willing and able to comply with scheduled visits, laboratory tests, and other study procedures.
  • 5\.Willing to refrain from consuming probiotic supplements and food containing added probiotics and/or prebiotics (e.g., yoghurts with live, active cultures or supplements) from screening until the end of the study (week 20\).
  • 6\.Able to walk 10 meters.
  • 7\.Able to get up from a chair.
  • 8\.BMI between 18 and 30 (inclusive) and body weight of at least 40 kgs.

Exclusion Criteria

  • 1\.Use of probiotics, prebiotics or antibiotics in the past 4 weeks (screened participants that are otherwise eligible may enrol into the study after a 4\-week wash\-out period).
  • 2\.Use of proton pump inhibitors in the last 3 months.
  • 3\.Chronic treatment with statins or other drugs with known myotoxicity.
  • 4\.Musculoskeletal or other disorder resulting in inability to perform physical function testing.
  • 5\.Presence of medical conditions causing secondary sarcopenia (i.e., stroke, osteoarthritis or other rheumatic diseases).
  • 6\.Presence of diseases or disorders that can impact muscle mass (i.e., cancer, CKD, chronic fatigue, etc.).
  • 7\.At risk for malnutrition (MNA\-SF less than or equal to 7\).
  • 8\.Milk or soy allergy.

Outcomes

Primary Outcomes

Not specified

Similar Trials